Using LC-MS/MS Analysis for PFAS Detection in Biological Samples and Serum
November 1st 2024Per- and polyfluoroalkyl substances (PFAS) are exceptionally versatile chemicals and have seemingly endless applications. Due to their persistent nature; prevalence in blood, food and environment; and emerging toxicity, there is a significant concern for their presence in the human body. Analysis is especially complicated due to background contamination in laboratory supplies and system. This paper will discuss sample preparation and LC-MS/MS analysis of an expanded panel of PFAS compounds in serum.
Meeting System Suitability for USP Abacavir and Lamivudine Tablets Assay
September 23rd 2024Abacavir and Lamivudine in combination are used with other medications to treat Human Immunodeficiency Virus (HIV) infection. In this technical note, we report the separation of Lamivudine from its related chiral and diastereomeric impurities in Abacavir and Lamivudine tablets per the USP monograph. The allowable adjustments pertaining to gradient separations are highlighted together with the necessary calculations that are required for the adjusted method conditions to remain compliant with the original monograph.
Nitrosamines, Meeting Regulatory Requirements
September 23rd 2024The necessity to analyse drug products for nitrosamines and NDSRIs (Nitrosamine Drug Substance Related Impurities) is well documented. In this document we provide an overview of 7 of our most recent applications in this area, together with links to the relevant technical notes.
Glucagon-Like-Peptide-1 (GLP-1) Analogues Applications Notebook
September 23rd 2024This applications notebook provides background information on GLP-1 analogues, together with information on the columns suitable for their purification and analysis. Finally it provides a range of reversed phase, size exclusion and preparative applications for a number of GLP-1 analogues.
Demystifying L/dp Ratio When Working with Allowable Adjustments
September 23rd 2024This white paper explores L/dp ratio for pharmacopeia allowable adjustments. It considers efficiency, explaining why L/dp ratio can be used as a proxy for efficiency, and illustrates the allowable adjustments through reviewing at a selection of different monographs.
Heat and High pH Forced Degradation of Antibodies on a Biozen dSEC-2 Column
January 22nd 2024This application note demonstrates the applicability of the Biozen dSEC-2 column in understanding the biophysical integrity monoclonal antibodies and related proteins. The hydrophilic nature of the Biozen dSEC-2 stationary phase shows favorable aggregate profiles for forced degradation work under high salt conditions which is a known challenge when working with more hydrophobic hybrid particles for these studies.
Size Exclusion Chromatography for the Determination of Protein
January 22nd 2024An understanding of analyte hydrodynamic radius (Rh), as well as size exclusion column pore size and distribution, are all critical in the understanding of how an analyte will behave by SEC. In this white paper, we will explore several protein standards with known hydrodynamic radii, and how this can be used to determine ideal size exclusion conditions for optimal method performance.